Overview
ABUS market data
Price History
ABUS price chart
Valuation & Profitability
- P/E (TTM)
- 5.45 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.13 – $5.38 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $876.1 · P/B 12.08 · P/S 4.58.
Company news
Arbutus Biopharma shares are trading higher after the company announced the filing of three international lawsuits seeking to enforce patent protecting LNP technology against Pfizer, BioNTech and certain or other affiliates.Benzinga · Jul 16, 2026, 1:08 PM
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their AffiliatesBenzinga · Jul 16, 2026, 11:39 AM
8-K filing — Arbutus Biopharma Corp (ABUS)SEC EDGAR · Jul 16, 2026, 11:31 AM
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K EstimateBenzinga · May 13, 2026, 11:45 AM